Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial
- 27 July 2022
- journal article
- research article
- Published by Elsevier in Psychiatry Research
- Vol. 316, 114737
Abstract
No abstract availableKeywords
Funding Information
- Tehran University of Medical Sciences and Health Services (46131)
This publication has 62 references indexed in Scilit:
- Site-Specific and Time-Dependent Activation of the Endocannabinoid System after Transection of Long-Range ProjectionsPLOS ONE, 2012
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophreniaTranslational Psychiatry, 2012
- Age of Onset of Schizophrenia: Perspectives From Structural Neuroimaging StudiesSchizophrenia Bulletin, 2011
- Pharmacological characterization of GPR55, a putative cannabinoid receptorPharmacology & Therapeutics, 2010
- Evaluating dose response from flexible dose clinical trialsBMC Psychiatry, 2008
- Cannabidiol displays unexpectedly high potency as an antagonist of CB1and CB2receptor agonistsin vitroBritish Journal of Pharmacology, 2007
- Treatment of Schizophrenia Negative Symptoms: Future ProspectsSchizophrenia Bulletin, 2006
- The search for the palmitoylethanolamide receptorLife Sciences, 2005
- Cannabis use predicts future psychotic symptoms, and vice versaAddiction, 2005
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960